Vipin Garg, Altimmune CEO
June 24, 2024 07:13 AM EDTUpdated 09:17 AM
R&D

Al­tim­mune says ‘dou­ble G’ drug has even bet­ter lean mass preser­va­tion da­ta in obe­si­ty tri­al up­date

Katherine Lewin

News Reporter

OR­LAN­DO – Al­tim­mune is back with a full Phase 2 analy­sis of its “dou­ble G” drug pemvidu­tide, with the com­pa­ny tout­ing it is much bet­ter …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

The End­points 11 win­ners: Big bets on AI, new fron­tiers in edit­ing, a neu­ro re­nais­sance and Chi­nese chem­istry

No­vo Nordisk to de­crease some in­sulin pen man­u­fac­tur­ing, tran­si­tion sup­ply

Ex­clu­sive: J&J folds car­dio­vas­cu­lar and meta­bol­ic drug unit

US gov­ern­ment re­news threats over J&J's pro­posed 340B re­bate mod­el

FDA ap­proves Bris­tol My­ers and Karuna's schiz­o­phre­nia drug, in mile­stone for psy­chi­a­try

sponsored

PD­Cs vs. AD­Cs: A New Fron­tier in Tar­get­ed Can­cer Ther­a­pies and the Po­ten­tial for De­vel­op­ment Part­ner­ships

A service from the Financial Times